Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Levels of the MicroRNA MiR-145 Predict Likelihood of Breast Cancer Recurrence

By LabMedica International staff writers
Posted on 07 Nov 2022

A recent study found that increased levels of the biomarker miR-145 (a microRNA) was linked to reduced risk of breast cancer recurrence following surgery. More...

While long-term outcomes have improved for patients with breast cancer, 20-30% will still develop recurrence, and identifying these patients remains a challenge. In this regard, investigators at the University of Galway (Republic of Ireland) examined whether miRNAs could predict which breast cancer patients were more likely to have a recurrence of the disease.

MicroRNAs (miRNAs) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia and cardiovascular conditions.

For this study, the investigators obtained blood samples from 124 breast cancer patients (with median age of 55.0 years) at diagnosis and while they were undergoing chemotherapy, and assessed their outcomes almost nine years later. Predetermined miRNAs were quantified from patient whole bloods using RT-qPCR, and miRNA expression profiles were correlated with recurrence-free (RFS), disease-free (DFS), and overall (OS) survival.

Results revealed that increased miR-145 expression greater than 0.222 was associated with improved RFS. In addition, increased miR-145 expression midway through the treatment regimen predicted improved DFS. Thus, increased miR-145 expression correlated with improved outcomes in early-stage breast cancer. However, no miRNAs correlated with overall survival.

First author Dr. Matthew G. Davey, a surgeon at the University of Galway, said, “We showed that increased expression of this biomarker, which was measured in patients’ blood samples during chemotherapy, actually predicted their long-term oncological outcome. We can predict those who are likely to suffer recurrence and those who will be free of recurrence.”

The predictive value of MiR-145 was discussed in the November 3, 2022, online edition of the Journal of the American College of Surgeons.

Related Links:
University of Galway 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Pan-Cancer Panel
TruSight Oncology 500
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.